by Cardio Diagnostics Inc | Jun 3, 2022 | News
Cardio Diagnostics, Inc. has pioneered a proprietary artificial intelligence-driven Integrated Genetic-Epigenetic Engine™ that enables improved diagnosis and prevention of cardiovascular disease The Company’s flagship product, Epi+Gen CHD™, is a highly sensitive and...
by Cardio Diagnostics Inc | May 25, 2022 | News
Pioneer of AI-driven, epigenetics-based clinical tests for cardiovascular disease moves for Chicago’s thriving biotech ecosystem and access to talent and resources CHICAGO, May 25, 2022 – Cardio Diagnostics, Inc., (“Cardio Diagnostics”), a company...
by Cardio Diagnostics Inc | Oct 27, 2021 | News
Cardio Diagnostics Wins “Clinical Diagnostics Solution of the Year” Award From BioTech Breakthrough Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry CHICAGO, October 27, 2021 – Cardio Diagnostics, Inc., a...
by Cardio Diagnostics Inc | Jan 28, 2021 | News
Cardio Diagnostics’ Epi+Gen CHD at-home sampling kit: Potential patients fill out a screening questionnaire that is reviewed by a board-certified clinician. If eligible for the test, a sampling kit is sent to their home. After the sample is collected, it is shipped...
by Cardio Diagnostics Inc | Sep 29, 2019 | News
Cardio Diagnostics received $225K in National Institutes of Health (NIH) funding to further develop our integrated genetic-epigenetic coronary heart disease risk screening technology.
by Cardio Diagnostics Inc | May 3, 2019 | News
Cardio Diagnostics won the Biotech Innovation Showcase Award and received a $5,000 grand prize at the annual IowaBio Partnering for Growth Conference.
